Continued growth of mainstay products and favorable currency tailwinds emerged as common themes as major players in Japan’s pharmaceutical industry released fiscal year and first quarter results and outlined key strategic plans for the rest of the year.
While Daiichi Sankyo Co., Ltd. revealed ambitious plans for its rapidly rising oncology star Enhertu, Chugai Pharmaceutical Co.,...







